EMCURE Emcure Pharmaceuticals Q3 FY25 results (Oct–Dec 2024) and concall
Emcure Pharmaceuticals reported strong Q3 FY25 results with robust revenue and adjusted PAT growth, primarily driven by its international business. The domestic segment saw some impact from restructuring and FCM issues, but management expects improvement. Strategic focus areas include Derma, Ophthalmology, and biologics, with significant progress on Semaglutide and Liposomal Amphotericin B.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 2,002 | 1,963 |
| EBITDA | 381 | 355 |
| Net profit | 202 | 156 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
